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Tumor Stress Inside Out: Cell-Extrinsic Effects of the
Unfolded Protein Response in Tumor Cells Modulate the
Immunological Landscape of the Tumor
Microenvironment
Navin R. Mahadevan and Maurizio Zanetti
The unfolded protein response (UPR) is a eukaryotic
cellular adaptive mechanism that functions to cope with
stress of the endoplasmic reticulum (ER). Accumulating
evidence demonstrates that the tumor microenviron-
ment contains stressors that elicit a UPR, which has
been demonstrated to be a cell-intrinsic mechanism cru-
cial for tumorigenesis. In addition, the UPR is a source
of proinflammatory signaling whose downstream medi-
ators may hamper antitumor immunity. We discuss
how the UPR may impair Ag presentation, which could
result in defective T cell priming, also leading to tumor
escape and growth. Further, we discuss the recent find-
ing that ER stress and attendant proinflammation can
be transmitted from ER-stressed tumor cells to myeloid
cells. The ideas presented suggest that, in addition to
being a cell-intrinsic mechanism of tumor survival,
the tumor UPR can serve as a cell-extrinsic regulator
of tumorigenesis by remodeling the immune response
in the tumor microenvironment. The Journal of
Immunology, 2011, 187: 4403–4409.
A
s early as the mid-1800s, histological examination
of neoplastic tissues revealed infiltration by inflam-
matory cells, suggesting a close association between
tumor development and inflammatory processes (1). Recent
studies added molecular detail to these early observations,
highlighting the role of tumor- and leukocyte-derived in-
flammation in promoting tumor growth. Master regulators of
inflammation, such as NF-kB and STAT3, were shown to be
crucial for tumor growth, and the tumorigenic roles of some
of their downstream effectors, including cytokines, chemo-
kines, and growth factors, have been elucidated. It is now
appreciated that the immune landscape of the tumor micro-
environment undergoes continuous dynamic remodeling, and
successful tumor outgrowth is contingent upon subversion
and escape from cell-extrinsic immune control (2). In addi-
tion to directly facilitating tumor growth, inflammatory sig-
nals in the tumor microenvironment can subvert the local
immune response against cancer cells by inhibiting APC and
CD8 T cell function, promoting regulatory T cell (Treg)
differentiation, and hampering the development of T cell
memory (3, 4). Although much work has focused on the
genetic underpinnings of tumor-derived inflammation, less
consideration has been given to microenvironmental and
metabolic factors that could initiate and sustain inflammation
in the tumor microenvironment. Recent evidence suggests
that pathophysiologic conditions unique to the tumor mi-
croenvironment initiate tumor cell stress signals that converge
upon the endoplasmic reticulum (ER), resulting in a condi-
tion termed “ER stress” (5). In this article, we discuss the
ER stress response, its determinants in the tumor micro-
environment, its newly appreciated role in tumorigenesis,
and new links between tumor cell ER stress and immune
cells.
ER stress and the unfolded protein response
The ER is the initial checkpoint for the biosynthesis, folding,
assembly, and modification of membrane-bound and secreted
proteins in eukaryotic cells. Increase in physiological demand
for protein folding or stimuli that disrupt the ability of proteins
to fold cause the accumulation of un-/misfolded proteins in the
ER lumen, resulting in a condition known as ER stress. This
activates intracellular signaling pathways known collectively as
the unfolded protein response (UPR), which facilitates cellular
adaptation to ER stress (6). In mammalian cells, the UPR is
initiated by three ER membrane-bound sensors, IRE1a,
ATF6, and PERK, which, in unstressed cells, are maintained
in an inactive state through luminal association with the ER
chaperone molecule GRP78 (7). When a cell experiences ER
stress, GRP78 disassociates from each of the three sensor
molecules to preferentially bind un-/misfolded proteins,
allowing each sensor to activate downstream-signaling cascades,
which act to normalize protein folding and secretion (8).
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Upon disassociation from GRP78, IRE1a autophosphor-
ylates, thereby activating its endonuclease function to remove
a 26-bp-segment from the Xbp-1 mRNA transcript. Trans-
lation of the shortened transcript yields an XBP-1 isoform
(XBP-1s) (9), which acts as a powerful driver of the pro-
duction of various ER chaperone proteins that function to
restore ER homeostasis by promoting proper protein folding,
maturation, secretion, and degradation. XBP-1s also pro-
motes the transcription of GRP78, XBP-1, thus establishing
a positive feedback loop (10). Activated ATF6 translocates to
the Golgi where it is cleaved into its functional form, which
acts in parallel with XBP-1s to restore ER homeostasis (11).
Upon release from GRP78, PERK phosphorylates eIF2a,
resulting in the selective inhibition of translation (12), effec-
tively reducing ER client protein load. If ER stress persists,
downstream signaling from PERK via ATF4 can also activate
the transcription factor, CHOP, which can initiate apoptosis
(13). The UPR intersects extensively with cell death signaling
and can upregulate caspases, proapoptotic transcription fac-
tors, and mitochondrial death pathways, as well as inhibit
antiapoptotic transcription factors (reviewed in Ref. 14).
The tumor microenvironment harbors noxae that elicit the UPR in
tumor cells
The tumor microenvironment differs markedly from that of
normal tissues. Most notably, tumors lack a well-developed
blood supply, which, coupled with the rapid proliferation of
tumor cells, leads to hypoxia, decreased glucose and amino acid
supply, and low extracellular pH (5). Compounding these
extrinsic noxae are tumor-intrinsic stressors, such as errors in
the biosynthesis of glycoproteins and lipids (15, 16), and
viruses (17), which collectively induce ER stress.
Hypoxia
Several lines of evidence indicate that hypoxia activates the
UPR in tumor cells. Microarray analysis of ras and c-myc
transformed mouse fibroblasts exposed to severe hypoxia in
vitro revealed that multiple elements of the UPR, including
Chop, Grp78, Xbp-1, and Atf4, are significantly upregulated
compared with normoxic cells. Human fibrosarcoma and
lung carcinoma cells upregulate GRP78 and increase XBP-1
splicing under hypoxic conditions in vitro (18, 19). Trans-
genic mice with spontaneous mammary carcinogenesis, in
which Xbp-1 splicing is marked by luciferase expression,
showed that XBP-1s bioluminescence correlates strongly with
increasing tumor hypoxia and colocalizes with CA-9, a marker
of hypoxia. In human colon cancer cells, hypoxia induces
PERK-dependent eIF2a phosphorylation and ATF4 pro-
duction (20).
Glucose deprivation
A high rate of tumor cell glycolysis and poor vascularization
combine to severely limit the glucose available to tumor cells
(21, 22). It has long been known that glucose deprivation
activates cellular stress responses. The GRP protein family,
including GRP78, was originally discovered because of its
upregulation in response to glucose deprivation (23). In their
in vivo model of microenvironment-driven tumor cell ER
stress, Spiotto et al. (24) demonstrated that XBP-1-luciferase
activity in spontaneous mammary tumors significantly in-
creases when tumor-bearing mice are treated with 2-deoxy-
glucose (a nonmetabolizable glucose analog) and that glucose
deprivation of tumor cells ex vivo causes a dramatic increase
in XBP1-luciferase expression. Taken together, these findings
demonstrate that hypoxia and low glucose are physiologically
relevant inducers of ER stress in tumors in vivo.
The UPR is activated in tumors and is essential for tumorigenesis
Accumulating evidence demonstrates UPR activation in tumor
cells and its critical role in solid tumor growth and progression.
Primary human tumor cells of several origins, including breast
(25), lung (26), liver (27), colon (28), prostate (29), and brain
(30), were shown to upregulate UPR pathways, including
GRP78, ATF6, and XBP-1 splicing, whereas peritumoral
areas do not. Additionally, in primary human melanoma,
liver, and breast cancer specimens, the level of GRP78 posi-
tively correlates with tumor progression (25, 27, 31).
The functional link between the UPR and tumorigenesis
was initially suggested by the finding that silencing of Grp78
in mouse fibrosarcoma cells inhibited growth in an in vivo
syngeneic transplantation model due, in part, to increased
tumor cell-specific memory T cell generation (32). The es-
sential role of GRP78 in tumorigenesis was confirmed when
it was shown that Grp78 heterozygous mice crossed with
MMTV-PyT heterozygous transgenic mice display signifi-
cantly decreased breast tumor proliferation, survival, and
angiogenesis compared with Grp78+/+, PyT mice (33). Simi-
larly, the conditional homozygous knockout of Grp78 in the
prostates of mice with Pten inactivation protects against pro-
state cancer growth (34).
More recent work demonstrated that UPR signaling
downstream of Grp78 facilitates tumor growth. Transformed
mouse fibroblasts deficient in Xbp-1 are more sensitive to
hypoxic stress in vitro than wild-type cells and do not grow as
tumors when injected into SCID mice. Consistent with these
findings, fibroblasts expressing a small interfering RNA
against Xbp-1 led to tumors that are smaller and exhibit de-
creased angiogenesis compared with tumors generated by
control cells when injected into mice (19, 35). Similarly, small
interfering RNA inhibition of XBP-1 in human fibrosarcoma
cells inhibits their growth and angiogenesis in a xenograft
model, and overexpression of XBP-1s in human fibrosarcoma
cells expressing a dominant-negative IRE1a mutant rescues
xenograft angiogenesis (19, 35). Additionally, human glioma
cells expressing a dominant-negative IRE1a mutant display
a decreased growth rate and impaired angiogenesis when
orthotopically transplanted into immunodeficient mice (18).
PERK signaling also supports tumor growth during con-
ditions of ER stress. The inactivation of ER stress signaling by
mutations of PERK, or by the introduction of a dominant-
negative PERK, in mouse fibroblasts and human colon cancer
cells results in tumors that are smaller, grow less rapidly, and
display impaired angiogenic ability when grafted into im-
munodeficient mice (20, 36). Taken together, these results
underscore the key contribution of the UPR in the growth
and progression of solid tumors of diverse origins.
The UPR intersects with cellular proinflammation
In addition to coping with an increased un-/misfolded protein
load in the ER, the UPR activates a proinflammatory cascade
with tumor-promoting and cell-survival properties. NF-kB is
one of the key inflammatory regulators inducible by the UPR
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(37). Each of the three UPR-signaling pathways activates NF-
kB translocation to the nucleus via distinct mechanisms and
consequent inflammatory gene transcription. PERK leads to
NF-kB activation via a unique mechanism in which trans-
lational inhibition reduces the ratio of IkB/NF-kB, thus per-
mitting the nuclear migration of NF-kB and transcription
of downstream inflammatory genes (38, 39). Upon auto-
phosphorylation, IRE1a forms a complex with TNF-aR–
associated factor 2 (TRAF2) at its cytosolic domain, and the
IRE1a–TRAF2 complex mediates direct IkB phosphoryla-
tion via IkB kinase (IKK), which leads to NF-kB activation.
Ire1a-deficient mouse fibroblasts under ER stress display re-
duced NF-kB activation and downstream TNF-a production
(40). Most recently, ATF6 was shown to participate in NF-
kB activation in an AKT-dependent manner (41). That the
UPR activates NF-kB via three independent mechanisms
suggests that the ER stress response is a key regulator of cel-
lular inflammation.
The UPR can also activate the JNK–AP-1 pathway of in-
flammation. The IRE1a–TRAF2 complex, aided by ASK and
AIP (42), can recruit JNK, which phosphorylates the tran-
scription factor, AP-1, leading to inflammatory gene expres-
sion. Supporting this model, IRE1a- or AIP-deficient fibro-
blasts under ER stress fail to activate JNK and downstream
inflammatory responses (42, 43).
Cross-talk between the UPR and inflammatory pathways is
not unidirectional. Inflammatory cytokines and reactive cell
metabolites can themselves induce the UPR. For instance,
TNF-a activates IRE1a, ATF6, and PERK in mouse fibro-
sarcoma cells by inducing the accumulation of reactive oxygen
species (ROS) (44). Additionally, IL-6, IL-1b, and LPS ac-
tivate the UPR in the liver in vivo (45). Furthermore, the
UPR can cause the accumulation of, and be induced by, ROS,
which were shown to induce phosphorylation of IkB in T cell
lymphoma and cervical cancer cells, permitting NF-kB–de-
pendent gene transcription (46). Although the UPR has an-
tioxidant function via PERK/ATF4/NRF2 signaling (47),
prolonged ER stress can cause the accumulation of ROS
via several mechanisms: accumulation of misfolded proteins
causes Ca2+ leak from the ER that stimulates mitochondrial
ROS production, which itself can increase ER Ca2+ depletion;
depletion of ATP to fuel protein folding induces mitochon-
drial respiration, whose byproducts include ROS; and forma-
tion of ROS as the consequence of formation and breakage
of disulfide bond and during normal protein folding (48).
Notably, limiting ROS accumulation in vivo using an anti-
oxidant attenuates ER stress (49), indicating that ROS them-
selves also elicit the UPR.
The phenotype and immunosuppressive effects of tumor-infiltrating
myeloid cells
Tumor-infiltrating myeloid cells can account for up to 30%
of leukocytes in tumors (50) and are key players in the cell-
extrinsic regulation of tumor growth. Because of their cru-
cial role in priming adaptive immunity, their subversion by
tumor cells represents one of the key mechanisms by which
tumors escape immune control. The tumor-infiltrating mye-
loid population was initially characterized as heterogenous,
comprising CD11b+/Gr1+ myeloid-derived suppressor cells
(MDSC), which contain, and may be precursors to (51),
subpopulations of CD11b+/Gr1+/F480+ tumor-associated
macrophages (TAM) and CD11b+/CD11c+ tumor-infiltrating
dendritic cells (TIDC) (52). Because of their ability to inhibit
T cell responses in vitro and in vivo (53, 54), and the initial
characterization of their phenotype as IL-10+/IL-122, cou-
pled with low levels of costimulatory molecules and Ag-pre-
sentation machinery, it was proposed that tumor-associated
CD11b+/Gr1+ myeloid cells possessed an anti-inflammatory
and suppressive phenotype (50). TIDC were first identified
as having an immature phenotype characterized by low levels
of MHC class I and II, as well as costimulatory molecule
(CD86/CD80) expression, which was assumed to be respon-
sible for the dysfunctional T cell priming and induction of
anergy observed in these cells (55).
Evidence has accumulated that implicates tumor- and host-
derived inflammatory processes in the accumulation and ac-
tivity of MDSC (reviewed in Ref. 56). The inflammation-
associated, proangiogenic factor vascular endothelial growth
factor stimulates the generation of MDSC in a paracrine and
autocrine manner (57, 58). Tumor- and host-derived IL-1b
and IL-6 cause increased MDSC burden, and increased
MDSC suppressive activity and tumor outgrowth are associ-
ated with tumor-derived IL-1b (59, 60). Cyclooxygenase-2–
derived PGE2 secreted by tumor cells polarize myeloid cells to
a suppressive phenotype (61, 62). Collectively, these data may
also explain recent findings that myeloid cells within the tu-
mor microenvironment can have an inflammatory/activated
phenotype while concurrently inhibiting antitumor immune
responses and aiding tumor growth. For instance, in tumor-
associated myeloid cells, generation of ROS crucial for the
inhibition of T cell responses can occur via arginase, a classical
M2 marker, but also via inducible NO synthase, an in-
flammatory marker (53, 63). Furthermore, as discussed be-
low, tumor-derived myeloid cells produce inflammatory
cytokines, such as IL-6, IL-23, and TNF-a, which play key
roles in tumor growth and in regulating antitumor immunity
(3). More recently, it was found that TIDC in melanoma
(64), lung carcinoma (65), and breast cancer (66) express high
levels of MHC class I/II, CD80, and CD86, yet they still
inhibit antitumor CD8 T cell responses in vitro and in vivo
as a result of inadequate Ag presentation and arginase pro-
duction (65–67). Taken together, these results underscore a
heretofore unappreciated phenotype of tumor-associated
myeloid cells as both inflammatory and suppressive (68).
The tumor-derived signals driving this mixed inflammatory/
suppressive phenotype have yet to be elucidated.
Although only a few studies have investigated Ag processing
and presentation in tumor-associated myeloid cells, studies
have shown that inhibition of TCR engagement of specific
peptide/MHC complexes by tumor-associated myeloid cells
can occur via ROS-mediated nitration (53, 69). Ag-indepen-
dent mechanisms of myeloid cell-mediated inhibition of
T cell function include local depletion of L-arginine via ar-
ginase upregulation or ROS production; release of immuno-
modulatory cytokines, such as TGF-b (51, 66); local cysteine
depletion (70); and induction of L-selectin downregulation on
T cells (71).
UPR involvement in Ag presentation
Jamora et al. (32) first showed that Grp78-deficient fibrosar-
coma cells evoke a more robust T memory cell response, re-
sulting in rejection of tumor cells with low immunogenicity.
The Journal of Immunology 4405
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This finding suggested the intriguing, but little-explored,
possibility that UPR signaling in tumor cells can impinge
upon tumor Ag presentation and the host antitumor immune
response. We showed that, although B cells mounting an
UPR following accumulation of a KDEL-retained protein in
the ER upregulate MHC class II and costimulatory molecules
(72), they present decreased levels of high-affinity peptide
complexed to MHC class II. Similarly, mouse thymoma cells
under palmitate or glucose deprivation-induced ER stress
decrease transgenic OVA Ag presentation on MHC class I
(73). These findings begin to suggest that APC under ER
stress undergo remodeling of the processing machinery,
yielding decreased presentation of high-affinity immunodo-
minant peptides and increased presentation of subdominant
or low-affinity peptides. This was the conclusion of a study
in human cancer cells treated with the histone deacetylase
inhibitor trichostatin A, which also upregulates ER stress
response genes while diminishing tapasin (74), a chaperone
molecule involved in quality control of MHC I/peptide
complexes in the ER (75). The relationship between ER
stress and tapasin is underscored by findings demonstrating
that specific induction of the UPR using thapsigargin, a
highly potent inducer of ER stress, causes downregulation of
tapasin transcription in lymphoma cells (72). Thus, a UPR
response in tumor cells and in APC may have the effect of
rearranging the hierarchy of the immunopeptidome.
UPR-linked effects on immunoregulatory signals
The UPR is linked to the production of several inflammatory,
tumorigenic cytokines: IL-6, IL-23, and TNF-a. A microarray
analysis of mouse lymphoma cells under in vitro pharmaco-
logical ER stress revealed transcriptional upregulation of mul-
tiple inflammatory genes, including Il-6, Il-23p19, Tnf-a,
Tlr2, and Cebpb (72). Furthermore, the levels of in vivo ER
stress, as measured by Grp78 expression, correlate with Il-6,
Il-23p19, and Tnf-a transcription in murine prostate cancer
cells growing in a heterotopic transplantation model (76).
CHOP is necessary for IL-23 production by dendritic cells
(77) and IL-6 and TNF-a by macrophages (78). Redundant
roles for IRE1a and PERK signaling in IL-6 and TNF-a
production in macrophages have been reported (78, 79).
Chromatin immunoprecipitation analysis also reveals that
XBP-1s binds to the promoters of Il-6 and Tnf-a; congru-
ently, Ire1a- or Xbp-1–deficient macrophages display im-
paired IL-6 and TNF-a production in response to pharma-
cological ER stress and infectious TLR agonism (79). The
UPR also synergizes with TLR4 agonism to result in robust
IL-23 secretion by macrophages (80). Interestingly, the UPR
in cancer cells also upregulates lipocalin 2 (81), an innate
immune inflammatory molecule whose first described func-
tion is the prevention of iron scavenging by bacterial side-
rophores (82). Notably, spontaneous breast cancer in mice
showed a decreased rate of progression in Lcn2-deficient mice
(83, 84).
UPR-linked proinflammatory mediators (85) in the tumor
microenvironment facilitate tumor growth and regulate im-
mune function (3). For example, inhibition of NF-kB by abla-
tion of IKKb in liver macrophages results in loss of TNF-a
and IL-6 production, which, in turn, impairs tumor growth
(86). Macrophage-specific deletion of IKKb leads to de-
creased production of PGE2 and IL-6, resulting in reduced
incidence of colitis-associated colorectal tumors (87). In a
model of lung cancer, IL-6 and TNF-a produced by myeloid
cells in response to tumor-derived versican (88) drive tumor
growth and progression in a TLR2-dependent manner. IL-23
produced by TAM blocks CD8 T cell infiltration into tumors
(89) and upregulates Treg differentiation in the tumor mi-
FIGURE 1. Relationships linking various ER stressors, the UPR, tumor
cells, and immune cells in the microenvironment. The umbrella (blue shad-
ing) represents the multifaceted influence of tumor ER stress/UPR on mye-
loid cells and elements of the adaptive T cell response. In this new framework,
the UPR acts as a cell-intrinsic tumor prosurvival factor (circular arrow). ER-
stressed tumor cells also may secrete cytokines and other factors that harness
myeloid cells in the tumor microenvironment, imprinting them with an in-
flammatory/suppressive phenotype (see text for description) that facilitates
tumor growth via T cell-dependent and -independent mechanisms (merging
arrows).
FIGURE 2. Dynamics of TERS from tumor cells to macrophages and consequences on tumor growth. A, Tumor cells experience ER stress (lightning bolts) as
the result of a variety of causal noxae and, as a consequence, mount a UPR. B, In addition to initiating prosurvival signaling through the UPR, tumor cells release
factors/signals to neighboring macrophages. In response, receiver macrophages undergo a UPR with attendant proinflammation (red aura). C, TERS-primed
tumor-infiltrating macrophages (red) may facilitate tumor growth by amplifying tumorigenic inflammation and impairing T cell-mediated antitumor immunity,
as suggested in Fig. 1.
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croenvironment (90). The complex interrelationships be-
tween tumor cells and immune cells under the umbrella of
ER stress are shown in Fig. 1.
Cell-extrinsic effects of the UPR on tumor-infiltrating immune cells
Thus far, the UPR has mostly been studied in the context of
tumor-intrinsic signaling that sustains survival and prolifer-
ation. The new paradigm of a UPR-signaling umbrella un-
der which proinflammation in the tumor microenvironment
originates, together with the key role of inflammation in de-
termining the phenotypic and functional complexity of TAM
and TIDC, raises the intriguing possibility that the tumor UPR
may impair host immune function in the tumor microenvi-
ronment in a cell-extrinsic manner. As a first step to investi-
gate this hypothesis, we modeled the interaction between
ER-stressed tumor cells and macrophages in the tumor mi-
croenvironment by culturing macrophages in the conditioned
medium of murine cancer cells experiencing pharmacological
or physiological ER stress in vitro. Surprisingly, macrophages
treated in this manner upregulated UPR signaling, as well as
the production of proinflammatory molecules, including
IL-6, IL-23, TNF-a, CD86, MIP-1a, and MIP-1b. This
“transmissible” ER stress (TERS) response is abrogated, in part,
in TLR4-deficient macrophages, whereas signaling through
either TLR2 or IL-6R, two likely candidates, is not involved.
Additionally, macrophages exposed to tumor ER stress-condi-
tioned medium upregulate arginase. The factor(s) responsible
for TERS were also operational in vivo (91).
The factor(s) responsible for TERS have yet to be identified;
studies of tumor cells deficient in each arm of the UPR will
help to elucidate the molecular basis of the interplay between
stressed tumor cells and macrophages. Recent findings showing
UPR-mediated intercell trafficking of soluble UPR proteins
(e.g., GRP78) (92) raise the intriguing possibility that ele-
ments of the UPR itself could communicate TERS. An alter-
native possibility implies a role for cyclooxygenase-2, which
is upregulated during ER stress (93) and was shown to be re-
sponsible for the production of factors that subvert macro-
phages in the tumor microenvironment (61). In addition,
future studies will have to address whether this new phenom-
enon is operational in spontaneously growing tumors. Fur-
thermore, although the proposed immunosuppressive sequelae
of TERS may be effected by already-known APC defects and/
or immunoregulatory molecules (e.g., cytokines, chemokines,
and small molecules), the novel role of the tumor UPR as the
initiator of these events remains intriguing.
Thus, a new picture emerges in which microenvironment-
induced ER stress in tumor cells initiates a tumorigenic, pro-
inflammatory cascade that can be propagated to infiltrating
macrophages, which concomitantly assume a phenotype en-
abling them to inhibit T cell responses. This phenotype fulfills
many of the inflammatory/suppressive criteria observed in
tumor-infiltrating myeloid cells. The cell-extrinsic influences
of tumor ER stress on macrophages is shown in Fig. 2.
The consequences of tumor UPR-mediated derangement of
APC, such as macrophages and dendritic cells, in the tumor
microenvironment remain unknown. It is possible that, via its
cell-extrinsic cues, the tumor UPR may ultimately manifest its
consequences in defective T cell priming. As noted above, one
consequence of ER stress in APC is impaired peptide pre-
sentation in the presence of adequate costimulatory molecule
expression. One may speculate that this could represent a
novel mechanism of inadequate T cell priming in addition to
the classical model of T cell anergy due to an insufficient
costimulatory “second signal.” T cell dysfunction could also
occur via Ag-independent mechanisms because the tumor
UPR affects the cytokine and metabolic profile of the APC. A
little explored possibility is that the UPR may cause immu-
nosuppression via the induction of Treg differentiation. It has
been well documented that Treg facilitate tumor growth by
suppressing Ag-specific adaptive T cell responses (94). Al-
though the relationship between tumor ER stress and Treg
differentiation is unknown, we reported the involvement of
the UPR in Il-10 transcription by differentiating human Treg
(95). Future work will need to elucidate these possibilities.
Conclusions
The UPR is an adaptive cell-signaling pathway that aids eu-
karyotic cells in coping with conditions in which the protein-
folding capacity of the ER is saturated or diminished. The
tumor microenvironment harbors multiple metabolic ER
stressors that induce a UPR in tumor cells, which is critical for
tumor cell survival and proliferation and has been correlated
with progression. Based on this evidence, the tumor UPR has
been most studied as a cell-intrinsic mechanism by which
tumor cells survive. Based on recent findings, we posit that
the tumor ER stress response can aid tumor growth in a cell-
extrinsic manner by inhibiting antitumor immunity via T cell-
independent and -dependent mechanisms.
Because UPR-inducing stimuli, such as hypoxia and glucose
deprivation, are unique to tumor microenvironment, UPR-
signaling molecules represent cancer-specific targets with
broad-spectrum applicability, because such stresses are found
in all solid-tumor microenvironments. Such strategies could
aim to induce ER stress while simultaneously curbing tumor
cell UPR signaling, thus leading to tumor regression, as has
been demonstrated (96). The new proposal of TERS, which
implicates host cells’ role as receivers/amplifiers of a patho-
genic tumor-derived UPR, further suggests that treatment
strategies targeting the UPR in the tumor microenvironment
may be doubly beneficial.
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